Nicholas C. Turner, Komal L. Jhaveri, Aditya Bardia, Naoki Niikura, Meritxell Bellet, Carlos H. Barrios, Véronique Diéras, Seock-Ah Im, Volkmar Mueller, Erwei Song, Jorge Luis Martinez Rodriguez, Igor Bondarenko, Mabel Alejandra Mardones, Ching-Wei Chang, Maria Louka, Miranda Craft, Pablo Diego Pérez-Moreno, Monika Patre, Sherene Loi. "Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.17_suppl.lba1006